贝伐珠单抗联合紫杉醇+顺铂化疗方案治疗肺腺癌患者的近远期效果观察  

Short-term and Long-term Effects of Bevacizumab Combined with Paclitaxel+Cisplatin Chemotherapy Regimen for Patients with Lung Adenocarcinoma

作　　者：王桂英 WANG Gui-ying(Department of Oncology,Jiamusi Cancer Hospital,Jiamusi,Heilongjiang,154007,China)

机构地区：[1]佳木斯市肿瘤医院肿瘤一科,黑龙江佳木斯154007

出　　处：《黑龙江医学》2023年第10期1178-1181,共4页Heilongjiang Medical Journal

摘　　要：目的:探讨贝伐珠单抗联合紫杉醇+顺铂(TP)化疗方案治疗肺腺癌患者的近远期效果及对患者血清甲状腺转录因子-1(TTF-1)、胸腺基质淋巴细胞生成素(TSLP)、乳酸脱氢酶(LDH)水平的影响。方法:前瞻性筛选2017年1月-2019年1月佳木斯市肿瘤医院收治的92例肺腺癌患者作为研究对象,按照随机数表法分为对照组和观察组,每组各46例。对照组采用TP化疗方案,3周为1个疗程;观察组采用贝伐珠单抗联合TP化疗方案,3周为1个疗程。比较两组患者治疗前后疾病控制率(DCR)、血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)、TTF-1、TSLP、LDH水平。比较两组患者不良反应发生情况、无病生存期(PFS)及总生存期(OS)。结果:观察组DCR高于对照组,差异有统计学意义(χ^(2)=5.134,P<0.05)。治疗3个疗程后,观察组血清CEA、CA125、CA199水平下降,且低于对照组,差异有统计学意义(t=46.131、11.047、14.706,P<0.05)。治疗3个疗程后,观察组血清TTF-1、TSLP、LDH水平下降,且低于对照组,差异有统计学意义(t=24.499、11.942、11.915,P<0.05)。两组患者不良反应发生情况比较,差异无统计学意义(χ^(2)=0.555,P>0.05)。观察组PFS、OS均长于对照组,差异有统计学意义(t=15.127、18.155,P<0.05)。结论:贝伐珠单抗联合TP化疗方案治疗肺腺癌患者的疗效优于单用TP化疗方案,能够进一步降低肿瘤负荷,延长患者生存期,降低血清TTF-1、TSLP、LDH水平。Objective:To investigate the short-term and long-term effects of bevacizumab combined with paclitaxel+cisplatin(TP)chemotherapy in the treatment of lung adenocarcinoma and its effects on the levels of serum thyroid transcription factor-1(TTF-1),thymic stromal lymphopoietin(TSLP)and lactate dehydrogenase(LDH).Methods:92 patients with lung adenocarcinoma admitted to the hospital from January 2017 to January 2019 were screened as study subjects and divided into control group and observation group according to the random number table method,with 46 cases in each group.The control group used TP chemotherapy regimen for 3 weeks as 1 course,and the observation group used bevacizumab combined with TP chemotherapy regimen for 3 weeks as 1 course.The disease control rate(DCR),serum carcinoembryonic antigen(CEA),glycoantigen 125(CA125),glycoantigen 199(CA199),TTF-1,TSLP,and LDH levels were compared before and after treatment in the two groups.The incidence of adverse reactions,disease-free survival(PFS)and overall survival(OS)were compared between the two groups.Results:The DCR in the observation group was higher than that in the control group,and the difference was statistically significant(χ^(2)=5.134,P<0.05).After 3 courses of treatment,the serum CEA,CA125 and CA199 levels in the observation group decreased and were lower than those in the control group,with statistically significant differences(t=46.131,11.047,14.706,P<0.05).After 3 courses of treatment,the serum TTF-1,TSLP and LDH levels in the observation group decreased and were lower than those in the control group,with statistically significant differences(t=24.499,11.942,11.915,P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(χ^(2)=0.555,P>0.05).The PFS and OS in the observation group were longer than those in the control group,and the differences were statistically significant(t=15.127,18.155,P<0.05).Conclusion:The efficacy of bevacizumab combined with TP chemotherapy regimen in treating pat

关 键 词：贝伐珠单抗 TP化疗方案 肺腺癌 糖类抗原125 生存期 

分 类 号：R734.2[医药卫生—肿瘤]